tirzepatide for iih Efficacy of Dual GIP/GLP‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study - Azzam - 2025 - Endocrinology, Diabetes & Metabolism semaglutide iih IIH (Idiopathic Intracranial

Tirzepatide as an insulin sensitizer

Mediation analyses show that early (24week) declines are only modestly weightmediated (18%31%), whereas by 72 weeks the reductions are largely weightmediated (57%87%), indicating an initial partly weightindependent signal that becomes predominantly weightlinked with sustained treatment [34]

Understanding the realistic timeline prevents both premature disappointment and unrealistic expectations

If you can safely take a dose up to four days late (making the gap as long as eleven days), the pharmacological profile clearly supports some flexibility in timing

Abnormal swelling or jaundice: These could be early signs of liver or gallbladder issues